High-Affinity TCR-T Development Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs provides a High-Affinity TCR-T Development Service to address key challenges in TCR-based immunotherapy, including off-target toxicity risks, low antigen sensitivity in solid tumors, and the difficulty of identifying rare neoantigen-specific TCRs. This service enables the discovery and optimization of highly specific, potent TCR candidates through proprietary affinity maturation technologies and safety screening platforms. By transforming naturally low-affinity TCRs into high-performance therapeutic assets with picomolar-level precision, Creative Biolabs supports efficient candidate selection and accelerates the transition from early discovery to clinical development.

Introduction

High-affinity TCR-T development is essential for targeting intracellular cancer antigens that are inaccessible to antibodies. Natural TCRs often lack the potency required for robust anti-tumor responses due to thymic selection. By utilizing directed evolution and structural biology, we can enhance TCR affinity by over a million-fold while maintaining strict specificity. Current literature confirms that this engineering is the key to overcoming the immunosuppressive tumor microenvironment in solid cancers.

Engineering Strategies for Enhancing the Function of TCR-Transgenic T Cells. (OA Literature) Fig.1 Engineering approaches to improve TCR-transgenic T Cell function.¹

Service

Creative Biolabs provides a suite of solutions designed to bridge the gap between basic TCR discovery and therapeutic application. We solve the primary challenge of natural TCRs, their inherent low affinity for self-antigens, by utilizing advanced directed evolution and structural modeling to enhance binding potency by up to a million-fold. Our services ensure that your lead candidates maintain an optimal affinity window, enabling them to distinguish between mutated neoantigens and wild-type proteins with exquisite sensitivity.

Our key capabilities cover the full development chain of TCR-T therapies: target-specific TCR discovery from immune repertoires or antigen-experienced T cells; affinity maturation to enhance peptide-MHC binding while preserving specificity; functional validation of cytotoxicity, cytokine secretion, and antigen sensitivity in tumor models; safety screening for off-target effects and cross-reactivity; as well as vector construction and T-cell engineering for preclinical research.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Creative Biolabs integrates multiple advanced platforms to support the discovery, optimization, and evaluation of high-affinity TCR-T candidates.

TCR Discovery and Repertoire Profiling	Affinity Optimization Platforms
High-throughput immune receptor profiling identifies antigen-responsive TCR sequences from antigen-stimulated or tumor-reactive immune cells. Candidate TCRs are cloned and validated for antigen specificity.	Targeted engineering optimizes TCR-peptide-MHC binding affinity and avidity via rational mutagenesis of variable domains and controlled variant screening.
Antigen Recognition Screening	Functional TCR-T Cell Evaluation
Engineered TCRs are assessed by pMHC binding, activation assays, and functional tests to select candidates with enhanced tumor recognition.	Tumor cell killing assays. Cytokine release analysis. Antigen sensitivity profiling. Activation marker analysis.

Our Workflow

To launch the service, clients are required to provide the target antigen sequence, the HLA restriction element, and any available parental TCR sequences.

Workflow of High-Affinity TCR-T Development. (Creative Biolabs Original)

Clients receive a detailed Technical Validation Report including KD kinetics, a Safety Cross-Reactivity Matrix against mimetic peptides, and the Optimized TCR Genetic Sequences ready for viral vector integration.

Core Benefits

Customized Affinity Maturation: Tailored directed evolution to achieve specific KD targets, ranging from micromolar to low picomolar levels.
Safety Screening: Negative selection against the human self-peptidome using phage libraries with over 6 billion variants to minimize off-target risks.
Flexible Therapeutic Formats: Support for traditional TCR-T cell engineering or the development of soluble bispecific T cell engagers.
Customized HLA Restriction: Expertise in developing TCRs for a wide array of HLA alleles beyond the common HLA.

FAQs

Q: How do you ensure that increasing TCR affinity doesn't lead to off-target toxicity?

A: We utilize a dual-track selection process: negative selection against the wild-type peptide and the human self-peptidome, followed by positive selection for the mutant. This ensures a broad "affinity window" is maintained.

Q: Can you develop TCRs for non-classical HLA alleles?

A: Yes! While many focus on HLA-A02, we have extensive experience with HLA-A11, A03, C08, and other alleles to broaden the patient population reachable by your therapy.

Q: What is the advantage of a soluble TCR bispecific over traditional TCR-T cells?

A: Soluble bispecifics can redirect the entire existing pool of polyclonal T cells to the tumor, whereas TCR-T requires the manufacture of a specific cell product for each patient.

Q: How do you handle the "induced fit" conformational changes during binding?

A: We use MD simulations and structural analysis to understand how the TCR and pHLA interact at a thermodynamic level, ensuring that the engineered TCR accounts for peptide dynamics.

Partner with Us

Creative Biolabs stands at the forefront of TCR technology, combining over 20 years of biology expertise with high-end synthetic biology tools. Our advantage lies in our ability to not just increase affinity, but to do so while preserving the "exquisite sensitivity" required for safe immunotherapy. We utilize Published Data to benchmark our platforms, ensuring our clients stay ahead of the competitive landscape in solid tumor targeting. Please feel free to contact our team for detailed information, customized solutions, and in-depth discussions about your specific project requirements.

Reference

Rath, Jan A, and Caroline Arber. "Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy." Cells vol. 9,6 1485. 18 Jun. 2020. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/cells9061485

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.